دورية أكاديمية
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy
| العنوان: | Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy |
|---|---|
| المؤلفون: | Vitello, Alessandro, Grova, Mauro, Pugliese, Daniela, Rizzello, Fernando, Lanzarotto, Francesco, Lavagna, Alessandro, Caccaro, Roberta, Cappello, Maria, Viola, Anna, Ribaldone, Davide Giuseppe, Principi, Mariabeatrice, Stasi, Elisa, Scribano, Maria Lia, Maida, Marcello, Soriano, Alessandra, Bezzio, Cristina, Bodini, Giorgia, Mocciaro, Filippo, Privitera, Antonio Carlo, Simondi, Daniele, Giuffrida, Enrica, D'Incà, Renata, Ricci, Chiara, Gionchetti, Paolo, Armuzzi, Alessandro, Orlando, Ambrogio, Daperno, Marco |
| المساهمون: | Vitello, Alessandro, Grova, Mauro, Pugliese, Daniela, Rizzello, Fernando, Lanzarotto, Francesco, Lavagna, Alessandro, Caccaro, Roberta, Cappello, Maria, Viola, Anna, Ribaldone, Davide Giuseppe, Principi, Mariabeatrice, Stasi, Elisa, Scribano, Maria Lia, Maida, Marcello, Soriano, Alessandra, Bezzio, Cristina, Bodini, Giorgia, Mocciaro, Filippo, Privitera, Antonio Carlo, Simondi, Daniele, Giuffrida, Enrica, D'Incà, Renata, Ricci, Chiara, Gionchetti, Paolo, Armuzzi, Alessandro, Orlando, Ambrogio, Daperno, Marco |
| سنة النشر: | 2022 |
| المجموعة: | Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto) |
| مصطلحات موضوعية: | Adalimumab, Effectivene, Real-world evidence, Safety, Ulcerative colitis |
| الوصف: | Background: Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods: This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results: We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion: Adalimumab is safe and effective for the treatment of ulcerative colitis. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34538764; info:eu-repo/semantics/altIdentifier/wos/WOS:000784240200010; volume:54; issue:3; firstpage:352; lastpage:357; numberofpages:6; journal:DIGESTIVE AND LIVER DISEASE; http://hdl.handle.net/2318/1846099Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85115121610 |
| DOI: | 10.1016/j.dld.2021.08.020 |
| الإتاحة: | https://doi.org/10.1016/j.dld.2021.08.020Test http://hdl.handle.net/2318/1846099Test |
| رقم الانضمام: | edsbas.1C00040E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.dld.2021.08.020 |
|---|